Is infliximab effective for induction of remission in patients with ulcerative colitis?
Lichtenstein
G R
GR
Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA. grl@mail.med.upenn.edu
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D023421:Models, Animal; D008992:Monkey Diseases / Q000503:physiopathology; D012074:Remission Induction; D013256:Steroids; D013792:Thalidomide / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; C402162:CDP 571; D013792:Thalidomide; D003520:Cyclophosphamide; D000069285:Infliximab